

Thrombocytopenia Treatments

Goal(s):

The goal of this initiative is to ensure thrombopoietin receptor agonists (TPOs) and tyrosine kinase inhibitors are used for their appropriate indications and for recommended treatment durations.

Length of Authorization:

- Up to 12 months

Requires PA:

Non-preferred drugs

Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030
- Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/

Approval Criteria		
1. What diagnosis is being treated?	Record ICD10 code.	
2. Is this an FDA approved indication?	Yes: Go to #3	No: Pass to RPh. Deny; medical appropriateness.
3. Is the diagnosis funded by OHP?	Yes: Go to #4	No: Pass to RPh. Deny; not funded by the OHP.
4. Is this for a renewal therapy for a patient previously prescribed fostamatinib?	Yes: Go to Renewal Criteria	No: Go to #5
5. Will the prescriber consider a change to a preferred product? Message: <ul style="list-style-type: none"> • Preferred products do not require a PA. • Preferred products are evidence-based reviewed for comparative effectiveness and safety by the Oregon Pharmacy & Therapeutics Committee. 	Yes: Inform prescriber of covered alternatives in class.	No: Go to #6
6. Is the request for avatrombopag (Doptelet®) or lusutrombopag (Mulpleta®) in a patient with chronic liver disease who is scheduled to undergo a procedure?	Yes: Approve for a maximum of 5 days for avatrombopag and for a maximum of 7 days for lusutrombopag.	No: Go to #7

Approval Criteria

7. Is the request for fostamatinib (Tavalisse™) and the patients has failed, or has contraindications to romiplostim and eltrombopag?

Yes: Approve for up to 3 months.

No: Pass to RPh. Deny; recommend trial of treatment(s) recommended in #7.

Renewal Criteria

1. Is the renewal request for fostamatinib and the patient has had liver function tests within the previous 30 days?

Yes: Approve for up to 12 months.

No: Pass to RPh. Advise provider to monitor liver function tests as recommended by prescribing materials.

*P&T/DUR Review: 1/2019 (KS)
Implementation: 3/1/2019*